<span item_type="fundamental" item_id="28bec3fa5ee91d3a81f7ddbc52882fc4" counter_id="ST/US/OSRH" env="prod"></span><span item_type="announcement" item_id="582041043300322177" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 627.75 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.1.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -3.778 M.</p><p></p><h3>Financial Metrics by Segment</h3><h4>Segment Revenue</h4><ul><li><strong>Net Sales</strong>: For the three months ended September 30, 2025, net sales were $627,747, a decrease of $195,249 or 24% compared to the same period in 2024. For the nine months ended September 30, 2025, net sales were $2,524,536, a decrease of $90,515 or 3% compared to the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840425/000121390025109054/ea0264521-10q_osrholdings.htm"></span></li></ul><h4>Operational Metrics</h4><ul><li><strong>Gross Profit</strong>: For the three months ended September 30, 2025, gross profit was $261,734, an increase of $82,641 or 46% compared to the same period in 2024. For the nine months ended September 30, 2025, gross profit was $463,201, a decrease of $188,014 or 29% compared to the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840425/000121390025109054/ea0264521-10q_osrholdings.htm"></span></li><li><strong>Operating Loss</strong>: For the three months ended September 30, 2025, operating loss was $3,803,465, an increase of $236,923 or 7% compared to the same period in 2024. For the nine months ended September 30, 2025, operating loss was $11,950,469, an increase of $1,871,291 or 19% compared to the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840425/000121390025109054/ea0264521-10q_osrholdings.htm"></span></li><li><strong>Net Loss</strong>: For the three months ended September 30, 2025, net loss was $3,194,874, a decrease of $161,659 or 5% compared to the same period in 2024. For the nine months ended September 30, 2025, net loss was $19,812,886, an increase of $10,823,499 or 120% compared to the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840425/000121390025109054/ea0264521-10q_osrholdings.htm"></span></li></ul><h4>Cash Flow</h4><ul><li><strong>Operating Cash Flow</strong>: For the nine months ended September 30, 2025, net cash used in operating activities was $3,258,041, an increase of $1,589,597 or 95% compared to the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840425/000121390025109054/ea0264521-10q_osrholdings.htm"></span></li><li><strong>Free Cash Flow</strong>: Not explicitly mentioned, but can be inferred from operating cash flow and capital expenditures.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840425/000121390025109054/ea0264521-10q_osrholdings.htm"></span></li></ul><h4>Unique Metrics</h4><ul><li><strong>Merger-Related Expenses</strong>: Approximately $8.5 million in merger-related expenses were recognized in connection with the Business Combination completed on February 14, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840425/000121390025109054/ea0264521-10q_osrholdings.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><h4>Core Business Focus</h4><ul><li><strong>Revenue Model Transition</strong>: RMC transitioned from a traditional purchase-and-resale model to a consignment-based arrangement, which is expected to enhance gross-margin stability in future periods.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840425/000121390025109054/ea0264521-10q_osrholdings.htm"></span></li><li><strong>R&amp;D Expenses</strong>: OSR Holdings expects to incur and report R&amp;D related expenses mainly from its subsidiaries actively engaged in R&amp;D at an estimated amount of $2.5 million to $3.0 million per quarter beginning in 2026, potentially increasing to $5.0 million to $6.0 million per quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840425/000121390025109054/ea0264521-10q_osrholdings.htm"></span></li></ul><h4>Non-Core Business</h4><ul><li><strong>Equity Line of Credit (ELOC)</strong>: OSR Holdings entered into an ELOC agreement providing for up to $80 million in potential capital. As of September 30, 2025, the Company had issued a total of 767,500 shares under the ELOC, raising gross proceeds of $741,937.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840425/000121390025109054/ea0264521-10q_osrholdings.htm"></span></li><li><strong>Convertible Bonds</strong>: The Company has a convertible note agreement with White Lion Capital, with an outstanding balance of $256,959 as of September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840425/000121390025109054/ea0264521-10q_osrholdings.htm"></span></li></ul><h4>Priority</h4><ul><li><strong>Nasdaq Compliance</strong>: The Company received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement. Management is actively monitoring the share price and evaluating options to regain compliance, including potential corporate or capital structure adjustments.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840425/000121390025109054/ea0264521-10q_osrholdings.htm"></span></li><li><strong>Strategic Acquisition</strong>: OSR Holdings announced a definitive share exchange agreement with Woori IO Co., Ltd., a Korean medical-device company, to become a wholly owned subsidiary. This acquisition aims to leverage OSRH’s governance, global partnerships, and clinical development resources to accelerate product development and commercialization.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840425/000121390025109054/ea0264521-10q_osrholdings.htm"></span></li></ul>

OSR | 10-Q: FY2025 Q3 Revenue: USD 627.75 K